The pharmacokinetics of angiotension converting enzyme (ACE) inhibitors enalapril (10 mg
orally) and its active metabolite, enalaprilat (10 mg intravenously) were studied in nine …

1. There is a body of circumstantial and direct evidence supporting the existence and
functional importance of a tissue based RAS at a variety of sites. 2. The relation between …

The inter-relationship between the pharmacokinetic and pharmacodynamic behaviour of
ACE inhibitors is reviewed. First, some of the methods which have been used to assess the …

The pharmacokinetics and pharmacodynamics of the angiotensin converting enzyme
inhibitor HOE 498 were investigated in 10 healthy normotensive male subjects. Serum …

1. The pharmacokinetics and pharmacodynamics of quinapril and its active metabolite
quinaprilat were studied in 20 subjects with renal function varying from normal to severe …

A randomized two‐way crossover study was conducted in 12 healthy volunteers to assess
the effect of food on the pharmacokinetics of quinapril (CI‐906) and its active metabolite, CI …

In a previous placebo-controlled, randomized, double-blind, cross-over study performed in 6
healthy volunteers, we investigated the pharmacokinetics and pharmacodynamics of a …

Overall, the partial therapeutic success of the major clinical trials of antihypertensive
treatment has highlighted some of the limitations of traditional therapeutic policies based …

Individualized approaches to antihypertensive therapy are being widely advocated. Ideally
these should incorporate rational prospective methods for drug and dosage selection but …

Aims To investigate, in healthy volunteers, the relationships between the plasma
concentrations (C, ng ml− 1) of zabiciprilat, the active metabolite of the angiotensin I …